Pharmacologic and Neurodynamic Interventions for Carpal Tunnel Syndrome: A Randomized Clinical Trial.

Arch Phys Med RehabilApr 18, 2026 (epub)

Francisco Hilarion Unda-Solano, Felipe Araya-Quintanilla, Héctor Gutiérrez-Espinoza et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the short-term effects of pharmacologic treatment and manual neurodynamic therapy (MNT) on pain, function, and kinesiophobia in 179 adults with mild-to-moderate carpal tunnel syndrome (CTS). Results indicated that all active interventions led to significant improvements, with the ibuprofen group showing the largest reduction in pain intensity of -19.3 mm.

Key findings

  • Ibuprofen group showed the largest pain reduction of -19.3 mm compared to control.
  • Gabapentin group had a pain reduction of -10.0 mm.
  • MNT group experienced a pain reduction of -4.7 mm.
  • All active interventions improved upper-limb disability and kinesiophobia compared to control.

Why it matters

Understanding the effectiveness of different interventions for carpal tunnel syndrome can guide clinicians in selecting appropriate treatments to alleviate symptoms and improve patient function.

Source

Published in Arch Phys Med Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.